Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse upgraded Korro Bio (KRRO) to Overweight from Neutral with a $21 price target The upgrade reflects confidence in Korro’s preclinical data, clinical strategy, and the market potential of lead program KRRO-121 for urea cycle disorders and hepatic encephalopathy, the analyst tells investors in a research note. KRRO-121 uses a de novo edit to stabilize glutamine synthetase, creating a compensatory pathway to reduce serum ammonia in patients with impaired urea cycle function, the firm says.